Provident Financial Services, Inc. Schedules Second Quarter Earnings Conference Call
Tartisan Nickel Corp. Retains Tetra Tech to Complete PFS Gap Analysis for the Kenbridge Nickel-Copper Project, Northwestern Ontario
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
American Ocean Minerals Announces Successful Completion of MV Anuanua Moana Expedition 7, Advancing Deep-Sea Environmental Baseline Research in the Cook Islands
Provident Bank Appoints Adriano Duarte EVP and Chief Financial Officer
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Tunkillia Pre-Feasibility Study Begins
Provident Bank Announces $1 Million in Grants to Ten New Jersey Non-Profit Organizations
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
Provident Bank Names Annamaria Vitelli EVP, Chief Wealth Officer and President of Beacon Trust
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
Dudick Promoted to SVP, Team Leader at Provident Bank
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
Anson Resources Engineering Study Confirms Green River as a Future Low-Cost Producer
Readers Nab 10 Ideal 'Safer' Dividend Dogs In April
Inflation, Debt, and a Housing Standstill: Provident Bank's 2026 Consumer Survey Captures the State of American Household Finances
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Implied Volatility Surging for Provident Financial Stock Options
Provident Financial Services Remains Compelling As Its Quality Shines Through
Analyst Note: Positive PEA Delivered — Rua Gold's Auld Creek Enters PFS Workstream Under New Zealand Fast-Track Approvals
Eagle Nuclear Energy Announces Commencement of Environmental Baseline Studies in Advance of PFS-Related Drill Program at Aurora
Stonegate Capital Partners Updates Coverage on Provident Financial Services Inc (PFS) 1Q26
Provident Financial Services, Inc. (PFS) Q1 2026 Earnings Call Transcript
Provident Financial Services, Inc. Declares Quarterly Cash Dividend
Provident Financial (PFS) Beats Q1 Earnings Estimates
Provident Financial (PFS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Provident Financial Services, Inc. Announces First Quarter Earnings
Riverview Bancorp (RVSB) Q4 Earnings and Revenues Miss Estimates
Provident Bank Expands ABL Team with the Addition of Bruce Gibson as First Vice President, Senior Relationship Manager
Provident Financial (PFS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Overwhelming Shareholder Support at 2026 Annual Meeting; Scandium Canada Enters the Year Fully Funded to Advance PFS, Drilling Campaign and Al-Sc Alloys Qualification